Official Gazette Notification Text
Official TranscriptGOVERNMENTOFINDIA MINISTRYOFHEALTH ANDFAMILYWELFARE DEPARTMENTOFHEALTHRESEARCH LOK SABHA UNSTARREDQUESTION NO. 2288 TOBE ANSWERED ON12TH DECEMBER, 2025 PROMOTION OFRESEARCH AND INNOVATION †2288.SHRIDINESH CHANDRAYADAV: SHRIGIRIDHARI YADAV: Will the Minister of HEALTHANDFAMILYWELFAREbe pleasedtostate: (a) the current status of the proposal to launch a new programme to promote research...
GOVERNMENTOFINDIA MINISTRYOFHEALTH ANDFAMILYWELFARE DEPARTMENTOFHEALTHRESEARCH LOK SABHA UNSTARREDQUESTION NO. 2288 TOBE ANSWERED ON12TH DECEMBER, 2025 PROMOTION OFRESEARCH AND INNOVATION †2288.SHRIDINESH CHANDRAYADAV:
SHRIGIRIDHARI YADAV:
Will the Minister of HEALTHANDFAMILYWELFAREbe pleasedtostate:
(a) the current status of the proposal to launch a new programme to promote research and innovationannouncedinthe Budget for the year2023-24; and
(b) if so, the detailsthereof? ANSWER THE MINISTER OFSTATEIN THE MINISTRYOFHEALTHAND FAMILYWELFARE
(SHRIPRATAPRAOJADHAV)
(a)and(b): The Department of Pharmaceuticals has informed that it has introduced the Promotionof Research andInnovation inPharma–MedTech (PRIP)Schemetosupport research and development in the pharmaceutical and medical technology industries in accordance with the Budget 2023–2024 announcement. The amended scheme and guidelines were notified on 1st October, 2025. The objective of the PRIP Scheme is to transform the Indian Pharma–MedTech sector from cost based to innovation-based growth by strengthening research infrastructure in the country. The rationale behind the recent amendments was to facilitate smooth implementation, bring greaterclarity ingovernance andmake benefit-sharing mechanismsmore effective.
The PRIP Scheme has two components, namely, Component A: Strengthening the research infrastructure through setting up of centers of excellence at National Institute of Pharmaceutical Education and Research (NIPERs) and Component B: Promotion of Research and Innovation in Pharma MedTech sector. Under component A, a total of seven centers of excellence have been set up, one at each of the seven NIPERs established at Mohali, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur and Hyderabad. Component B is for providing financial assistance to support research and development (R&D) for development of products and technologies or expeditious validation of R&D outputs for market launch and large-scale commercialisation in three priority areas, namely new medicines, complex generics and biosimilars, and novel medical devices. BothEarly Stage Projects and Later Stage Projects are eligible for disbursement of financial assistance.
Under this component, the Department of Pharmaceuticals has invited applications for research and innovationprojectsfrom pharmaceutical andMedTech industry andstartups.
Further, in December 2023, Indian Council of Medical Research (ICMR) started MedTech Mitra platform in partnership with the Central Drugs Standard Control Organization (CDSCO), under the guidance of NITI Aayog. The MedTech Mitra portal has been operationalized on ICMR website.
This platform provides guidance to innovators from start-ups, industry and academia for the development of MedTech products. Multiple inter-departmental/inter-ministerial partners such as Department of Pharmaceuticals, Ministry of Micro, Small & Medium Enterprises (MSME), Bureau ofIndianStandards,NationalAccreditationBoard forTestingandCalibrationLaboratories(NABL), Government e-Market place are the core partners of this initiative besides the ICMR’s National Animal Resource Facility for Biomedical Research (NARFBR) and Indian Clinical Trial and EducationNetwork (INTENT).
****